<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21681">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882712</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40191</org_study_id>
    <nct_id>NCT01882712</nct_id>
  </id_info>
  <brief_title>Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel
      0.5% applied topically once daily for 29 days versus vehicle control, in subjects with
      moderate to severe chronic persistent vascular facial erythema
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite success on both CEA (Clinician Erythema  Assessment ) and PSA (Patient Self Assessment)</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>1-grade improvement on both CEA and PSA at Hours 3, and 6 after Pre-dose (T0)on Day 29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite improvement on both CEA (Clinician Erythema  Assessment ) and PSA (Patient Self Assessment)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>1-grade improvement on both CEA and PSA at 30 minutes after pre-dose (T0) on Day 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Erythema</condition>
  <arm_group>
    <arm_group_label>CD07805/47 Gel 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47 Gel Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparator arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 Gel 0.5%</intervention_name>
    <arm_group_label>CD07805/47 Gel 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 Gel Placebo</intervention_name>
    <arm_group_label>CD07805/47 Gel Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, who is at least 18 years of age or older at screening visit.

          -  Presence of chronic persistent vascular facial erythema for ≥ 3 months by history.

          -  A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0)
             on Baseline/Day 1.

          -  A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on
             Baseline/Day 1.

        Exclusion Criteria:

          -  More than 10 facial inflammatory lesions (papules, pustules, and nodules).

          -  Presence of areas of significant scaling or crusting on the face.

          -  Presence of psoriatic lesions on the face.

          -  Presence of any other dermatological condition of the face that, in the opinion of
             the Investigator, may significantly interfere with the interpretation of the clinical
             trial results.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diane Rudisill</last_name>
    <phone>+1 6098608260</phone>
    <email>diane.rudisill@galderma.com</email>
  </overall_contact>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
